By Fineline Cube 
China-based Zhaoke Ophthalmology (HKG: 6622) announced the signing of a Memorandum of Agreement (MOA) with FAREVA, a leading French contract manufacturing organization. This strategic partnership positions Zhaoke Ophthalmology as a trusted partner for FAREVA’s clients seeking drug manufacturing solutions in China.
Collaboration Details
Dr. Li Xiaoyi, Chairman, Executive Director, and CEO of Zhaoke Ophthalmology, emphasized that this collaboration highlights the company’s R&D and manufacturing capabilities under global standards. It represents a significant milestone in Zhaoke Ophthalmology’s global strategic expansion.
Global Manufacturing Base
Zhaoke Ophthalmology plans to leverage its advanced manufacturing base in Nansha, Guangzhou, to promote innovative ophthalmic therapies to the international market. This initiative aims to address unmet global medical needs.
FAREVA’s Global Presence
FAREVA, established in 1990, operates 41 production sites across 13 countries. In 2025, the company reported an operating revenue of €2.22 billion. This collaboration underscores FAREVA’s commitment to enhancing its global footprint in the pharmaceutical manufacturing sector.-Fineline Info & Tech